Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Barlesi, F."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
    Autorzy:
    Mogenet A; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.
    Finetti P; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Denicolai E; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.
    Boudou-Rouquette P; Department of Medical Oncology, Cochin Hospital, AP-HP, Paris, France-University of Paris Descartes, ARIANE, CARPEM, Paris, France.
    Goldwasser F; Department of Medical Oncology, Cochin Hospital, AP-HP, Paris, France-University of Paris Descartes, ARIANE, CARPEM, Paris, France.
    Lumet G; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Ceccarelli M; Sylvester Comprehensive Cancer Center, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
    Birnbaum D; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Bedognetti D; Division of Translational Medicine, Research Branch, Sidra Medicine, Doha, Qatar.; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
    Mamessier E; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Barlesi F; Paris-Saclay University and Medical Oncology, Gustave Roussy, Cancer Campus, Villejuif, France.
    Bertucci F; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France. .; Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, 232, Bd de Sainte-Marguerite, 13009, Marseille, France. .
    Tomasini P; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d'Oncologie Prédictive, Aix Marseille Univ, Marseille, France.
    Pokaż więcej
    Źródło:
    Journal of translational medicine [J Transl Med] 2023 Sep 19; Vol. 21 (1), pp. 637. Date of Electronic Publication: 2023 Sep 19.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Carcinoma, Non-Small-Cell Lung*/drug therapy
    Carcinoma, Non-Small-Cell Lung*/genetics
    Lung Neoplasms*/drug therapy
    Lung Neoplasms*/genetics
    Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Retrospective Studies ; Biomarkers
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer.
    Autorzy:
    Bilous M; MONC team, Inria Bordeaux Sud-Ouest, Talence, France.; Institut de Mathématiques de Bordeaux, Bordeaux University, Talence, France.
    Serdjebi C; SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.
    Boyer A; SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
    Tomasini P; Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
    Pouypoudat C; Radiation oncology department, Haut-Lévêque Hospital, Pessac, France.
    Barbolosi D; SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.
    Barlesi F; SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
    Chomy F; Clinical oncology department, Institut Bergonié, Bordeaux, France.
    Benzekry S; MONC team, Inria Bordeaux Sud-Ouest, Talence, France. .; Institut de Mathématiques de Bordeaux, Bordeaux University, Talence, France. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2019 Sep 10; Vol. 9 (1), pp. 13018. Date of Electronic Publication: 2019 Sep 10.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Models, Theoretical*
    Brain Neoplasms/*secondary
    Carcinoma, Non-Small-Cell Lung/*pathology
    Lung Neoplasms/*pathology
    Radiosurgery/*methods
    Brain Neoplasms/surgery ; Carcinoma, Non-Small-Cell Lung/surgery ; Humans ; Longitudinal Studies ; Lung Neoplasms/surgery
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
    Autorzy:
    Pujol JL; Department of Thoracic Oncology, Montpellier Regional University Hospital, Montpellier, France.; Laboratory of Biostatistics and Epidemiology, University Institute for Clinical Research, Montpellier, France.
    Coffy A; Laboratory of Biostatistics and Epidemiology, University Institute for Clinical Research, Montpellier, France.
    Camerini A; Medical Oncology, Ospedale Villa Scassi, Genoa, Italy.
    Kotsakis A; Hellenic Oncology Research Group (HORG), Athens, Greece.
    Mencoboni M; Medical Oncology, Versilia Hospital-ASL Toscana Nord-Ovest, Lido di Camaiore, LU, Italy.
    Gusella M; AULSS5 Polesana, UOC Oncologia, Ospedale Santa Maria della Misericordia, Rovigo, Italy.
    Pasini F; Oncology Service, Casa di Cura Pederzoli, Peschiera del Garda (VR), Italy.
    Pezzuto A; Thoracic and Cardiovascular Science Department S. Andrea Hospital, Sapienza University, via Grottarossa, Rome.
    Banna GL; Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.
    Bilir C; Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
    Samantas E; Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
    Barlesi F; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Centre d'Investigation Clinique, Marseille, France.
    Roch B; Department of Thoracic Oncology, Montpellier Regional University Hospital, Montpellier, France.
    Guillou A; Medical Direction Department, Pierre Fabre Oncology, place Abel Gance Boulogne-Billancourt, France.
    Daurès JP; Laboratory of Biostatistics and Epidemiology, University Institute for Clinical Research, Montpellier, France.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2019 Aug 20; Vol. 14 (8), pp. e0220988. Date of Electronic Publication: 2019 Aug 20 (Print Publication: 2019).
    Typ publikacji:
    Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Anemia/*epidemiology
    Antineoplastic Agents, Phytogenic/*administration & dosage
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Lung Neoplasms/*drug therapy
    Vinorelbine/*administration & dosage
    Administration, Metronomic ; Administration, Oral ; Anemia/chemically induced ; Antineoplastic Agents, Phytogenic/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Clinical Trials, Phase II as Topic ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Progression-Free Survival ; Time Factors ; Vinorelbine/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.
    Autorzy:
    Schneider BK; Iowa State University College of Veterinary Medicine, Ames, Iowa, USA.
    Boyer A; SMARTc Unit, Centre de Recherche en Cancérologie de Marseille Unité Mixte de Recherche (UMR) Inserm U1068, Aix Marseille University, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Ciccolini J; SMARTc Unit, Centre de Recherche en Cancérologie de Marseille Unité Mixte de Recherche (UMR) Inserm U1068, Aix Marseille University, Marseille, France.
    Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Wang K; Mayo Clinic, Rochester, Minnesota, USA.
    Benzekry S; Iowa State University College of Veterinary Medicine, Ames, Iowa, USA.; Team Modelisation en Oncologie, Inria Bordeaux Sud-Ouest, Institut de Mathématiques de Bordeaux, Talence, France.
    Mochel JP; Iowa State University College of Veterinary Medicine, Ames, Iowa, USA.
    Pokaż więcej
    Źródło:
    CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Aug; Vol. 8 (8), pp. 577-586. Date of Electronic Publication: 2019 May 09.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Bevacizumab/*administration & dosage
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Cisplatin/*administration & dosage
    Lung Neoplasms/*drug therapy
    Pemetrexed/*administration & dosage
    Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Bevacizumab/pharmacokinetics ; Cell Line, Tumor ; Cisplatin/pharmacokinetics ; Drug Administration Schedule ; Female ; Humans ; Mice ; Models, Biological ; Pemetrexed/pharmacokinetics ; Treatment Outcome ; Xenograft Model Antitumor Assays
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.
    Autorzy:
    Imbs DC; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.
    El Cheikh R; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.
    Boyer A; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Ciccolini J; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.
    Mascaux C; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Lacarelle B; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.
    Barlesi F; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Barbolosi D; SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.
    Benzekry S; MONC Team, Inria Bordeaux Sud-Ouest, Talence, France.; Institut de Mathématiques de Bordeaux, UMR 5251, University of Bordeaux and CNRS, Talence, France.
    Pokaż więcej
    Źródło:
    CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2018 Jan; Vol. 7 (1), pp. 42-50. Date of Electronic Publication: 2017 Dec 07.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Models, Theoretical*
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Bevacizumab/*therapeutic use
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Lung Neoplasms/*drug therapy
    Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Bevacizumab/administration & dosage ; Bevacizumab/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Administration Schedule ; Humans ; Lung Neoplasms/pathology ; Mice ; Proof of Concept Study ; Xenograft Model Antitumor Assays
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Autorzy:
    Tomasini P; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. .; Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. .
    Serdjebi C; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. .; Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix Marseille University, Marseille 13015, France. .
    Khobta N; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. .
    Metellus P; Department of Neurosurgery, Aix-Marseille University, Marseille 13005, France. .
    Ouafik L; Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. L'.; Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix Marseille University, Marseille 13015, France. L'.
    Nanni I; Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix Marseille University, Marseille 13015, France. .
    Greillier L; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. .; Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. .
    Loundou A; Statistics Department, Aix Marseille University, Marseille 13005, France. .
    Fina F; Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix Marseille University, Marseille 13015, France. .
    Mascaux C; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. .; Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. .
    Barlesi F; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations department. Aix Marseille University, Marseille 13015, France. fabrice.barlesi@ap-hm.fr.; Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. fabrice.barlesi@ap-hm.fr.
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2016 Dec 18; Vol. 17 (12). Date of Electronic Publication: 2016 Dec 18.
    Typ publikacji:
    Journal Article; Observational Study
    MeSH Terms:
    Brain Neoplasms/*genetics
    Brain Neoplasms/*secondary
    Carcinoma, Non-Small-Cell Lung/*genetics
    ErbB Receptors/*genetics
    Lung Neoplasms/*genetics
    Proto-Oncogene Proteins p21(ras)/*genetics
    Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/therapeutic use ; Brain Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
    Autorzy:
    Elharrar X; Multidisciplinary Oncology and Therapeutic Innovations department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France. .; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France. .
    Barbolosi D; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.
    Ciccolini J; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.
    Meille C; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.
    Faivre C; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.
    Lacarelle B; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.
    André N; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France.; Assistance Publique Hôpitaux de Marseille, Centre d'Essais Précoces en Cancérologie de Marseille APHM CLIP2, Aix Marseille University, Marseille, France.; Paediatry Oncology Unit, Assistance Publique Hôpitaux de Marseille, Marseille, France.
    Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France. Fabrice.Barlesi@ap-hm.fr.; SMARTc Pharmacokinetics Unit, Aix Marseille University, Inserm S_911 CRO2, Marseille, France. Fabrice.Barlesi@ap-hm.fr.; Assistance Publique Hôpitaux de Marseille, Centre d'Essais Précoces en Cancérologie de Marseille APHM CLIP2, Aix Marseille University, Marseille, France. Fabrice.Barlesi@ap-hm.fr.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2016 Apr 20; Vol. 16, pp. 278. Date of Electronic Publication: 2016 Apr 20.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Models, Theoretical*
    Antineoplastic Agents, Phytogenic/*administration & dosage
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Vinblastine/*analogs & derivatives
    Administration, Metronomic ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Middle Aged ; Survival Rate ; Vinblastine/administration & dosage ; Vinblastine/adverse effects ; Vinblastine/pharmacokinetics ; Vinorelbine
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
    Autorzy:
    LeCaer H; Services de Pneumologie, CH Route Montferrat 83300, Draguignan, France. />Barlesi F
    Corre R
    Jullian H
    Bota S
    Falchero L
    Vergnenegre A
    Dujon C
    Delhoume JY
    Chouaid C
    Pokaż więcej
    Corporate Authors:
    GFPC 0504 Team
    Źródło:
    British journal of cancer [Br J Cancer] 2011 Oct 11; Vol. 105 (8), pp. 1123-30. Date of Electronic Publication: 2011 Sep 20.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Lung Neoplasms/*drug therapy
    Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease Progression ; Docetaxel ; Drug Administration Schedule ; Erlotinib Hydrochloride ; Geriatric Assessment ; Humans ; Lung Neoplasms/pathology ; Quinazolines/administration & dosage ; Taxoids/administration & dosage ; Gemcitabine
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.
    Autorzy:
    Pujol JL; Montpellier Academic Hospital, Hôpital Arnaud de Villeneuve, Avenue du Doyen Giraud, 34295 Montpellier Cedex 5, France. />Molinier O
    Ebert W
    Daurès JP
    Barlesi F
    Buccheri G
    Paesmans M
    Quoix E
    Moro-Sibilot D
    Szturmowicz M
    Bréchot JM
    Muley T
    Grenier J
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2004 Jun 01; Vol. 90 (11), pp. 2097-105.
    Typ publikacji:
    Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Models, Theoretical*
    Antigens, Neoplasm/*blood
    Biomarkers, Tumor/*blood
    Carcinoma, Non-Small-Cell Lung/*pathology
    Lung Neoplasms/*pathology
    Neoplasm Staging/*methods
    Aged ; Female ; Humans ; Keratin-19 ; Keratins ; Male ; Middle Aged ; Patient Care Planning ; Prognosis ; Survival Analysis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies